Celgene and Acceleron's luspatercept successful in late-stage beta thalassemia study [Seeking Alpha]
CELGENE (CELG)
Last celgene earnings: 10/31 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celgene.com
Company Research
Source: Seeking Alpha
A Phase 3 clinical trial, BELIEVE , evaluating Celgene (NASDAQ: CELG ) and Acceleron Pharma's (NASDAQ: XLRN ) luspatercept in adults with beta-thalassemia-associated anemia met the primary endpoint . The results were presented at ASH in San Diego. A statistically significant proportion patients in the treatment group experienced hematological improvement compared to placebo, defined as at least a 33% reduction from baseline in red blood cell count (RBC) transfusion burden. Specifically, 21.4% (n=48/224) of patients receiving luspatercept experienced red blood cell responses compared to 4.5% (n=5/112) for control (p 7.6% (n=17/224) of patients in the treatment group experienced at least a 50% reduction in RBC transfusion burden versus 1.8% (n=2/112) for placebo (p=0.0303). On the safety front, 15.2% (n=34/223) of patients receiving luspatercept experienced serious treatment-emergent adverse events (TEAEs) compared to 5.5% (n=6/109) for control. 13.9% (n=31/223) of pati
Show less
Read more
Impact Snapshot
Event Time:
CELG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELG alerts
High impacting CELGENE news events
Weekly update
A roundup of the hottest topics